The importance of knowing how vancomycin ismeasured when interpreting its pharmacokinetic results

Therapeutic Drug Monitoring

Volumn 35, Issue 3, 2013, Pages 416-

  Zhao, Wei ^a   Jacqz Aigrain, Evelyne ^a,b,c  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; IMMUNOGLOBULIN M; VANCOMYCIN;

ANALYTIC METHOD; CREATININE BLOOD LEVEL; DRUG SCREENING; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FOLLOW UP; HUMAN; IMMUNOASSAY; LETTER; NEWBORN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; HUMANS; MEDICAL LABORATORY PERSONNEL; PARAPROTEINS; RHEUMATOID FACTOR; VANCOMYCIN;

EID: 84880065872     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182866a99     Document Type: Letter

References (8)

1. Allegaert K, Anderson BJ, van den Anker JN, et al. Renal drug clearance in preterm neonates: relation to prenatal growth. Ther Drug Monit. 2007;29:284-291. (Pubitemid 47262257)
2. Kimura T, Sunakawa K, Matsuura N, et al. Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates. Antimicrob Agents Chemother. 2004;48:1159-1167. (Pubitemid 38405469)
3. Lo YL, van Hasselt JG, Heng SC, et al. Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination. Antimicrob Agents Chemother. 2010;54:2626-2632.
4. Marqués-Miñana MR, Saadeddin A, Peris JE. Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline. Br J Clin Pharmacol. 2010;70:713-720.
5. Grimsley C, Thomson AH. Pharmacokinetics and dose requirements of vancomycin in neonates. Arch Dis Child Fetal Neonatal Ed. 1999;81:F221-F227. (Pubitemid 29503334)
6. Capparelli EV, Lane JR, Romanowski GL, et al. The influences of renal function and maturation on vancomycin elimination in newborns and infants. J Clin Pharmacol. 2001;41:927-934. (Pubitemid 32786565)
7. Zhao W, Kaguelidou F, Biran V, et al. External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings. Br J Clin Pharmacol. DOI: 10.1111/j.1365-2125. 2012.04406.x.
8. Legatt DF, Blakney GB, Higgins TN, et al. The effect of paraproteins and rheumatoid factor on four commercial immunoassays for vancomycin: implications for laboratorians and other health care professionals. Ther Drug Monit. 2012;34:306-311.